Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Robert Shorr, Ph.D, D.I.C, CEO, Cornerstone Pharmaceuticals, discusses how physicians can understand a new oncology drug, starting with knowing its safety limitations. He also explains the structure and…
Gary Falk, MD, MS, Professor of Medicine, Director, Center for Esophageal and Swallowing Disorders, Cleveland Clinic, discusses a new treatment Barrett’s esophagus, radiofrequency ablation, useful in two particular…
NEW YORK (Reuters Health) – Active surveillance of prostate cancer, with intervention offered for progressive disease, appears to be safe even for intermediate-risk disease in men over the…
NEW YORK (Reuters Health) – New research confirms that tubular carcinoma (TC) of the breast has an excellent prognosis and goes on to show that outcomes are better…
NEW YORK (Reuters Health) – Transfusion of two rather than one unit of partially HLA-matched umbilical cord blood (UCB) appears to reduce the risk of relapse in leukemia…
NEW YORK (Reuters Health) – In an update to its 2003 guidelines for stage IV non-small-cell lung cancer (NSCLC) chemotherapy, the American Society of Clinical Oncology (ASCO) recommends…
NEW YORK (Reuters Health) – In an update to its 2002 guidelines, the US Preventive Services Task Force (USPSTF) is now recommending that mammographic screening for breast cancer…
NEW YORK (Reuters Health) – Use of erythropoiesis-stimulating agents in US cancer patients undergoing chemotherapy has increased 10-fold since their introduction, yet there’s been no associated decline in…
NEW YORK (Reuters Health) – After breast-conserving surgery for invasive cancer, mammographic density is a risk factor for local recurrence, particularly in women who don’t undergo radiotherapy, investigators…
NEW YORK (Reuters Health) – In patients with locoregionally advanced squamous-cell carcinoma of the head and neck (LASCCHN), the survival benefit of adding cetuximab to radiotherapy is still…
